Drive value with
novel immuno-oncology
Y-BIOLOGICS
Next Leader in Immuno-Oncology
WHAT WE DO | Y-Biologics
Developing next-generation multispecific antibody therapeutics.
FACT SHEET | Key Figures
Y-Biologics continuously builds expertise in antibody technologies through ongoing research and development of antibody-based new drugs, thereby enhancing the company's competitiveness.
48 employees and growing
Employees
staff
Technology transfer for antibody research and development
Technology transfer
cases
cases
Joint development
Open Innovation
121 patent applications to date
Patent applications
cases
62 patents registered
Patent registration
cases
(as of June 2025)
NEWS | NEWS
View the latest news from Y-Biologics.
Dec 2, 2025
인투셀, 고형암 치료제 美 FDA 이어 식약처 임상 1상 IND 승인 획득
Nov 27, 2025
인투셀, 항B7-H3 ADC 후보물질 ‘ITC-6146RO’ 美 임상1상 승인
PARTNERSHIP | PARTNERSHIP
Introducing Y-Biologics’ partners.
Drive value with
novel immuno-oncology
Drive value with
novel immuno-oncology
Y-BIOLOGICS
Y-BIOLOGICS
Next Leader in Immuno-Oncology
Developing next-generation multispecific antibody therapeutics.
Developing next-generation multispecific antibody therapeutics.
Developing next-generation multispecific antibody therapeutics.
WHAT WE DO | Y-Biologics
FACT SHEET | Key Figures
Y-Biologics continuously builds expertise in antibody technologies through ongoing research and development of antibody-based new drugs, thereby enhancing the company's competitiveness.
Y-Biologics continuously builds expertise in antibody technologies through ongoing research and development of antibody-based new drugs, thereby enhancing the company's competitiveness.
Y-Biologics continuously builds expertise in antibody technologies through ongoing research and development of antibody-based new drugs, thereby enhancing the company's competitiveness.
48 employees and growing
48 employees and growing
Employees
staff
Technology transfer for antibody research and development
Technology transfer for antibody research and development
Technology transfer
Technology transfer
cases
Joint development
Joint development
Open Innovation
Open Innovation
cases
121 patent applications to date
121 patent applications to date
Patent applications
Patent applications
cases
Patent registration
Patent registration
62 patents registered
62 patents registered
cases
48 employees and growing
48 employees and growing
Employees
staff
Technology transfer for antibody research and development
Technology transfer for antibody research and development
Technology transfer
cases
cases
Joint development
Joint development
Open Innovation
121 patent applications to date
121 patent applications to date
Patent applications
cases
62 patents registered
62 patents registered
Patent registration
cases
(as of June 2025)
NEWS | NEWS
NEWS | NEWS
NEWS | NEWS
Here’s the latest news from Y-Biologics.
Here’s the latest news from Y-Biologics.
Here’s the latest news from Y-Biologics.
Dec 2, 2025
하반기 제약바이오 길라잡이 : 미국 헬스케어 정책 하반기에는 국내 우호적으로 변화 기대. YTD 부진했던 코스피 제약사 2분기 호실적 반등 기대. 코스닥 바이오텍은 기술수출 모멘텀과 글로벌 주요 R&D 트렌드 부합하는 기업들 주목
Dec 1, 2025
하반기 제약바이오 길라잡이 : 미국 헬스케어 정책 하반기에는 국내 우호적으로 변화 기대. YTD 부진했던 코스피 제약사 2분기 호실적 반등 기대. 코스닥 바이오텍은 기술수출 모멘텀과 글로벌 주요 R&D 트렌드 부합하는 기업들 주목
Nov 27, 2025
하반기 제약바이오 길라잡이 : 미국 헬스케어 정책 하반기에는 국내 우호적으로 변화 기대. YTD 부진했던 코스피 제약사 2분기 호실적 반등 기대. 코스닥 바이오텍은 기술수출 모멘텀과 글로벌 주요 R&D 트렌드 부합하는 기업들 주목
Nov 17, 2025
하반기 제약바이오 길라잡이 : 미국 헬스케어 정책 하반기에는 국내 우호적으로 변화 기대. YTD 부진했던 코스피 제약사 2분기 호실적 반등 기대. 코스닥 바이오텍은 기술수출 모멘텀과 글로벌 주요 R&D 트렌드 부합하는 기업들 주목
Dec 2, 2025
인투셀, 고형암 치료제 美 FDA 이어 식약처 임상 1상 IND 승인 획득
Nov 27, 2025
인투셀, 항B7-H3 ADC 후보물질 ‘ITC-6146RO’ 美 임상1상 승인
PARTNERSHIP | PARTNERSHIP